cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE.
isn't the only enzyme that investigators have been chasing as a potential target of Alzheimer's drugs.
Companies to advance beta-secretase
(BACE) inhibitors, which hold potential for slowing the progression of this devastating neurodegenerative disease
The company advanced the first beta-secretase
inhibitor into the clinic for the treatment of Alzheimer's disease in 2006.
Starting in 1997 researchers started to look for the gene that directs cells to make beta-secretase
Identification of high affinity beta-secretase
inhibitors using fragment-based lead generation (Jeffrey S.
INDIANAPOLIS, July 13, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from its non-clinical study in genetically engineered mice examining combination therapy with the murine version of the beta-amyloid antibody N3pG and beta-secretase
inhibitor BACE (LY2811376).
to develop products from CoMentis' beta-secretase
inhibitor program, including lead compound CTS-21166, which is being developed as a disease-modifying treatment for Alzheimer's disease.
Milestone achieved for BI's initiation of Phase 1 study in beta-secretase
(BACE) inhibitor program
Awards were made at a special scientific briefing and luncheon to three scientists who have all individually made significant contributions to the understanding of Alzheimer's by shedding light on beta-secretase
and gamma-secretase enzyme activities in the brain - enzymes that play an important role in Alzheimer's disease.
The drug acts by inhibition of beta-secretase
(BACE1), one of two enzymes that produce beta-amyloid by breaking down its parent molecule, known as amyloid precursor protein (APP).
The company has two fundamental technology platforms: (i) aspartic protease inhibitors, including beta-secretase
inhibitors for Alzheimer's disease; and (ii) nicotinic acetylcholine receptor (nAChR) agonists and antagonists for the treatment of angiogenesis mediated diseases and cognitive disorders.